I wrote earlier this week about genome sequencing of famous dead celebrities, pointing out that the trend seems full of ethical complexities. Genome news More broadly, sequencing the genomes of non-celebrities from hundreds or thousands of years ago can be important research. A new NYT piece covers such work on the Swahili people. Such research […]
Weekly reads: genome sequencing, chemical reprogramming 2.0 Read More »
It’s been almost seventeen years that I’ve been a professor here at UC Davis Medical School. It feels like home. I enjoy teaching our first-year medical students each year. Some end up doing research in my lab. Our school recently got a nice write-up over at STAT News by Usha Lee McFarling on the diversity
Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes
Review of where Kimera Labs fits into sphere of exosome companies Read More »
Where do things stand with potential applications of CRISPR and other gene editing technologies in patients? Overall, things are looking very positive. CRISPR human trials This week the third big international human genome editing meeting took place in London. The summit addressed numerous potential clinical applications. It was good to see the agenda included quite
Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked Read More »
It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech. There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads
Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »
I’m sure many of you remember He Jiankui, the guy who made CRISPR babies. He ended up serving three years in jail in China. He seems to be trying for something of a comeback since his release. Were He Jiankui invitations a mistake? Some prestigious places have even invited him to give talks, which seemed
Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma Read More »
Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way. As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the
Skepticism on the Bryan Johnson anti-aging extravaganza Read More »
It’s always exciting when your lab has a new paper and my team just published a study knocking out the H3f3a gene in mice, which codes for histone H3.3 protein. We found that loss of this gene leads to lethality at a late stage of embryonic development. There were also indications of more specific phenotypes
Weekly reads: H3.3 on the brain, Texas bill, HSCs Read More »
The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past
3rd Invitrx warning highlights FDA oversight weakness Read More »
I tend to perhaps over-focus on human CRISPR or gene editing, but other applications including in agriculture are definitely going to be huge. CRISPR in agriculture One that I’ve been following for a long time is the use of CRISPR to prevent cows from growing horns. Why is that a big deal? Just in the
Weekly reads: CRISPR chicks, HSCs, sequencing Mendel Read More »